BEONE MEDICINES LTD-ADR (ONC) Stock Fundamental Analysis
USA - NASDAQ:ONC - US07725L1026 - ADR
311.86 USD
+1.38 (+0.44%)
311.86 USD
0 (0%)
Overall ONC gets a fundamental rating of 5 out of 10. We evaluated ONC against 534 industry peers in the Biotechnology industry. The financial health of ONC is average, but there are quite some concerns on its profitability. ONC is growing strongly while it also seems undervalued. This is an interesting combination
1. Profitability
1.1 Basic Checks
In the past year ONC was profitable.
In the past year ONC had a positive cash flow from operations.
ONC had negative earnings in each of the past 5 years.
In the past 5 years ONC always reported negative operating cash flow.
1.2 Ratios
ONC has a better Return On Assets (-3.68%) than 87.64% of its industry peers.
Looking at the Return On Equity, with a value of -6.15%, ONC belongs to the top of the industry, outperforming 89.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.68% | ||
| ROE | -6.15% | ||
| ROIC | N/A |
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ONC has a better Gross Margin (85.37%) than 87.64% of its industry peers.
In the last couple of years the Gross Margin of ONC has remained more or less at the same level.
ONC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
2. Health
2.1 Basic Checks
ONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ONC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ONC has been increased compared to 5 years ago.
ONC has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.22 indicates that ONC is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 7.22, ONC is doing good in the industry, outperforming 78.09% of the companies in the same industry.
The Debt to FCF ratio of ONC is 5.47, which is a neutral value as it means it would take ONC, 5.47 years of fcf income to pay off all of its debts.
ONC has a Debt to FCF ratio of 5.47. This is amongst the best in the industry. ONC outperforms 92.13% of its industry peers.
ONC has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
ONC's Debt to Equity ratio of 0.26 is on the low side compared to the rest of the industry. ONC is outperformed by 69.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.47 | ||
| Altman-Z | 7.22 |
ROIC/WACCN/A
WACC4.78%
2.3 Liquidity
A Current Ratio of 1.94 indicates that ONC should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.94, ONC is doing worse than 76.22% of the companies in the same industry.
ONC has a Quick Ratio of 1.71. This is a normal value and indicates that ONC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ONC (1.71) is worse than 78.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.71 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 217.74% over the past year.
The Revenue has grown by 47.67% in the past year. This is a very strong growth!
The Revenue has been growing by 55.91% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)217.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.68%
Revenue 1Y (TTM)47.67%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.76%
3.2 Future
Based on estimates for the next years, ONC will show a very strong growth in Earnings Per Share. The EPS will grow by 94.77% on average per year.
The Revenue is expected to grow by 18.91% on average over the next years. This is quite good.
EPS Next Y128.58%
EPS Next 2Y69.11%
EPS Next 3Y51.39%
EPS Next 5Y94.77%
Revenue Next Year40.27%
Revenue Next 2Y31.06%
Revenue Next 3Y25.91%
Revenue Next 5Y18.91%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.03, the valuation of ONC can be described as very cheap.
ONC's Price/Earnings ratio is rather cheap when compared to the industry. ONC is cheaper than 99.06% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. ONC is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 50.19, the valuation of ONC can be described as expensive.
Based on the Price/Forward Earnings ratio, ONC is valued cheaper than 89.70% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ONC to the average of the S&P500 Index (22.53), we can say ONC is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.03 | ||
| Fwd PE | 50.19 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, ONC is valued cheaply inside the industry as 91.01% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 181.35 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ONC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ONC's earnings are expected to grow with 51.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y69.11%
EPS Next 3Y51.39%
5. Dividend
5.1 Amount
ONC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
311.86
+1.38 (+0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners33.86%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change5.79%
Market Cap34.25B
Revenue(TTM)32.74B
Net Income(TTM)-1651114000
Analysts81.43
Price Target330.21 (5.88%)
Short Float %17.51%
Short Ratio5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.55
Dividend Growth(5Y)N/A
DP-30.61%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2148.49%
Min EPS beat(2)1187.13%
Max EPS beat(2)3109.85%
EPS beat(4)3
Avg EPS beat(4)1518.68%
Min EPS beat(4)-22.81%
Max EPS beat(4)3109.85%
EPS beat(8)4
Avg EPS beat(8)536.4%
EPS beat(12)5
Avg EPS beat(12)344.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.52%
Min Revenue beat(2)-1.25%
Max Revenue beat(2)6.29%
Revenue beat(4)3
Avg Revenue beat(4)2.7%
Min Revenue beat(4)-1.25%
Max Revenue beat(4)6.29%
Revenue beat(8)7
Avg Revenue beat(8)13.13%
Revenue beat(12)11
Avg Revenue beat(12)13.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.16%
PT rev (3m)16.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1258.99%
EPS NY rev (1m)33.15%
EPS NY rev (3m)238.8%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)9.73%
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)2.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.03 | ||
| Fwd PE | 50.19 | ||
| P/S | 7.45 | ||
| P/FCF | 181.35 | ||
| P/OCF | 70.15 | ||
| P/B | 9.08 | ||
| P/tB | 9.52 | ||
| EV/EBITDA | N/A |
EPS(TTM)61.97
EY19.87%
EPS(NY)6.21
Fwd EY1.99%
FCF(TTM)1.72
FCFY0.55%
OCF(TTM)4.45
OCFY1.43%
SpS41.88
BVpS34.36
TBVpS32.77
PEG (NY)0.04
PEG (5Y)N/A
Graham Number218.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.68% | ||
| ROE | -6.15% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.37% | ||
| FCFM | 4.11% |
ROA(3y)-19.6%
ROA(5y)-21.52%
ROE(3y)-30.77%
ROE(5y)-32.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y0.23%
F-Score6
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.51% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z | 7.22 |
F-Score6
WACC4.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)20.18%
Cap/Sales(5y)27.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)217.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.68%
EPS Next Y128.58%
EPS Next 2Y69.11%
EPS Next 3Y51.39%
EPS Next 5Y94.77%
Revenue 1Y (TTM)47.67%
Revenue growth 3Y53.06%
Revenue growth 5Y55.91%
Sales Q2Q%40.76%
Revenue Next Year40.27%
Revenue Next 2Y31.06%
Revenue Next 3Y25.91%
Revenue Next 5Y18.91%
EBIT growth 1Y89.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year178.04%
EBIT Next 3Y67.31%
EBIT Next 5Y55.15%
FCF growth 1Y110.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y136.32%
OCF growth 3YN/A
OCF growth 5YN/A
BEONE MEDICINES LTD-ADR / ONC FAQ
What is the ChartMill fundamental rating of BEONE MEDICINES LTD-ADR (ONC) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ONC.
Can you provide the valuation status for BEONE MEDICINES LTD-ADR?
ChartMill assigns a valuation rating of 7 / 10 to BEONE MEDICINES LTD-ADR (ONC). This can be considered as Undervalued.
How profitable is BEONE MEDICINES LTD-ADR (ONC) stock?
BEONE MEDICINES LTD-ADR (ONC) has a profitability rating of 3 / 10.
Can you provide the financial health for ONC stock?
The financial health rating of BEONE MEDICINES LTD-ADR (ONC) is 4 / 10.
Can you provide the dividend sustainability for ONC stock?
The dividend rating of BEONE MEDICINES LTD-ADR (ONC) is 0 / 10 and the dividend payout ratio is -30.61%.